Aim The aim of this study was to assess the outcome of transcatheter aortic valve replacement (TAVR) in patients with cancer. Methods This is a retrospective study from the nationwide FinnValve registry on 2130 consecutive patients who underwent TAVR for severe AS from January 2008 to October 2017. Results In this cohort, 417 patients (19.6%) had history of cancer and 113 (5.3%) had an active malignancy at the time of TAVR. Patients with any malignancy had similar late mortality than patients without any malignancy (at 7 years, 65.1% vs. 59.3%, adjusted HR 1.105, 95%CI 0.892–1.369). At 7 years, cancer-related mortality was 22.5% among patients with preoperative cancer, and 11.0% in those without preoperative cancer (p
Citera det här
Biancari, F., Dahlbacka, S., Juvonen, T.
, Virtanen, M. P. O., Maaranen, P., Jaakkola, J., ... Valtola, A. (2020). Favorable outcome of cancer patients undergoing transcatheter aortic valve replacement
. International Journal of Cardiology